Nanobiotix reported 50,968,893 shares outstanding as of October 31, 2026, alongside 54,726,179 theoretical voting rights and 54,704,061 exercisable voting rights.
NBTX · Nanobiotix S.A. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
NANOBIOTIX announced management appearances at the Jefferies Global Healthcare Conference on Monday, November 16, 2026, and the UBS Global Biopharma Conference on Tuesday, November 17, 2026, in London.
Nanobiotix reported final Phase 1 data for JNJ-1900 (NBTXR3) with immune checkpoint inhibitors in anti-PD-1-resistant primary cutaneous melanoma. The overall response rate was 41.7% (10/24), including 4 complete responses, with median overall survival of 17.8 months.
Nanobiotix reported that as of September 30, 2026 it had 50,967,610 shares outstanding, with 54,729,543 theoretical voting rights and 54,707,425 exercisable voting rights.
Nanobiotix S.A. appointed Arnd Christ chief financial officer and executive board member effective October 1, 2026; Bart Van Rhijn will step down as chief financial & business officer and board member after five years.
Nanobiotix reported a €34.3 million net loss for the six months ended June 30, 2026, with €110.9 million in cash and cash equivalents. Its May 2026 Global Offering raised approximately $100 million (corresponding to €86.1 million) gross and €80.1 million net.
Nanobiotix reported €110.9 million in cash and cash equivalents as of June 30, 2026, funding operations into 2029.
Nanobiotix S.A. reported 50,941,528 shares outstanding as of August 31, 2026, with 54,701,246 theoretical voting rights and 54,679,128 exercisable voting rights.